{"analyses":[{"ciLowerLimit":"0.82","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.19","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Hazard Ratio (HR)","paramValue":"0.99"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.4"},{"groupId":"OG001","value":"86.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2884"},{"groupId":"OG001","value":"2877"}],"units":"Participants"}],"description":"Invasive disease-free survival (iDFS, excluding second primary invasive cancers of non-breast origin) for the combination of at least 5 years endocrine therapy and 2-year palbociclib treatment versus at least 5 years endocrine therapy alone in patients with histologically confirmed HR+/HER2- invasive early breast cancer (EBC) at 4 years. iDFS excluding second primary invasive cancers of non-breast origin is defined as the time from randomization to the date of the first event: local/regional invasive ipsilateral recurrence, contralateral invasive breast cancer, distant recurrence, or death from any cause. Second primary invasive cancers of non-breast origin will not be considered as events for this endpoint. Direct comparison between arms used time to iDFS events and Kaplan-Meier Log-rank analysis. Due to the medians not yet achieved, the percentage of patients considered iDFS at 4 years is reported.","groups":[{"description":"Palbociclib at a dose of 125 mg orally once daily, Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle for a total duration of 2 years, in addition to standard adjuvant endocrine therapy for a duration of at least 5 years.","id":"OG000","title":"Palbociclib Plus Endocrine Therapy (Arm A)"},{"description":"Standard adjuvant endocrine therapy for a duration of at least 5 years.","id":"OG001","title":"Endocrine Therapy Alone (Arm B)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"4 years","title":"Invasive Disease Free Survival (iDFS) Excluding Second Primary Invasive Cancers of Non-breast Origin.","type":"SECONDARY","unitOfMeasure":"percentage of patients"}